NTLA - Company ID 0001652130
Intellia Therapeutics, Inc. trades as NTLA and has a market capitalization of $2.19 B, making it the #2063 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $67.67M, up 16.9% from the prior year and net income of -$412.69M. This page tracks Intellia Therapeutics, Inc. through 679 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Intellia Therapeutics, Inc.'s revenue grew from $16.48M to $67.67M, a compound annual growth rate of 17.0%. Net profit margin compressed from -192.0% to -609.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| SCHEDULE 13G | - | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
| SCHEDULE 13G | - | 2026-04-29 |
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 - Intellia Therapeutics
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics
Intellia Therapeutics to Participate in Upcoming Investor Conferences - Intellia Therapeutics
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock - Intellia Therapeutics
The largest companies sharing Intellia Therapeutics, Inc.'s SEC industry classification (in vitro & in vivo diagnostic substances).
Intellia Therapeutics, Inc. (NTLA) has a market capitalization of $2.19 B as of 2026-07-09, ranking #2063 among US-listed companies.
Intellia Therapeutics, Inc. reported revenue of $67.67M for fiscal year 2025, an increase of 16.9% year over year.
In its latest fiscal year Intellia Therapeutics, Inc. reported a net loss of $412.69M.